勃林格殷格翰的能倍乐效果如何？

It is a long-acting anticholinergic drug with similar affinity for five choline receptors (M1-M5). In vivo and in vitro studies have shown that Respimat has a dose-dependent and sustainable 24-hour inhibition of methacholine-induced bronchoconstriction. Respimat's bronchial dilation effect has outstanding localization selectivity. Let’s find out how effective Boehringer Ingelheim’s Respimat is?

In a research trial, 298 patients with chronic obstructive pulmonary disease were included and randomly divided into an observation group (149 cases) and a control group (149 cases). The observation group was treated with Respimat for 3 months, and the control group was treated with aminophylline for 3 months.

The results showed that the lung function index of patients treated with Respimat was significantly better than that of the control group, and the difference was statistically significant.

In terms of the incidence of adverse reactions, the incidence in the Respimat treatment group was 3.3% and that in the control group was 10.7%. The difference between the two groups was statistically significant. Patients treated with Respimat can effectively improve lung function indicators with remarkable results.

Boehringer Ingelheim is a pharmaceutical company dedicated to human biopharmaceutical chemistry and animal health products. It is also the world's largest privately held pharmaceutical company. Boehringer Ingelheim's main research areas include: immune and respiratory diseases, cardiovascular and metabolic diseases, central nervous system diseases, and tumors. Boehringer Ingelheim has a complete biopharmaceutical industry chain, from genetic engineering of cells to manufacturing, and commercial production of off-the-shelf medicines for external industrial customers.

The recommended dose of Respimat is once a day, with two sprays each time. The effect of Respimat can last for 24 hours. Patients are advised not to overdose. Respimat should be used at the same time every day, and, since COPD is a long-term disease, Respimat can be used every day, not just when you have breathing problems.

Developed by Boehringer Ingelheim, it has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with chronic obstructive pulmonary disease (COPD), making it easier for them to breathe.